Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NEK2 | P51955 | 8/20 | 0.55 |
| ▸ | PLK1 | P53350 | 16/20 | 0.52 |
| ▸ | PLK3 | Q9H4B4 | 6/20 | 0.46 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.46 |
| ▸ | NUAK1 | O60285 | 2/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.46 |
| ▸ | PIM1 | P11309 | 2/20 | 0.46 |
| ▸ | KDR | P35968 | 2/20 | 0.46 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4409823 | 0.93 | NEK2 (0.64) | NEK2PLK1PLK3PIK3CDNUAK1 | |
| SCHEMBL4412237 | 0.85 | PLK1 (0.54) | NEK2PLK1PLK3PIK3CDNUAK1 | |
| SCHEMBL4406623 | 0.84 | PLK1 (0.57) | NEK2PLK1PLK3PIK3CDNUAK1 | |
| SCHEMBL4999620 | 0.83 | NEK2 (0.61) | NEK2PLK1PLK3PIK3CDNUAK1 | |
| SCHEMBL4406129 | 0.82 | PLK1 (0.76) | NEK2PLK1PLK3PIK3CDNUAK1 | |
| SCHEMBL2977487 | 0.82 | PLK1 (0.70) | NEK2PLK1PLK3PIK3CDNUAK1 | |
| SCHEMBL5062477 | 0.81 | PLK1 (0.62) | NEK2PLK1PLK3PIK3CDNUAK1 | |
| SCHEMBL4405335 | 0.79 | PLK1 (0.54) | NEK2PLK1PLK3PIK3CDNUAK1 | |
| SCHEMBL4402759 | 0.79 | NEK2 (0.62) | NEK2PLK1PLK3PIK3CDNUAK1 | |
| SCHEMBL2973679 | 0.78 | PLK1 (0.72) | NEK2PLK1PLK3PIK3CDNUAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1924572-B1 | REGIOSELECTIVE PROCESS FOR PREPARING BENZIMIDAZOLE THIOPHENES | SMITHKLINE BEECHAM CORP (US) | 2009-12-30 | — | — | EP | disclosed |
| US-20080249301-A1 | Regioselective Process for Preparing Benzimidazole Thiophenes | SMITHKLINE BEECHAM CORPORATION | 2008-10-09 | — | — | US | disclosed |
| US-20080249301-A1 | Regioselective Process for Preparing Benzimidazole Thiophenes | SMITHKLINE BEECHAM CORPORATION | 2008-10-09 | — | — | US | disclosed |
| US-20080249301-A1 | Regioselective Process for Preparing Benzimidazole Thiophenes | SMITHKLINE BEECHAM CORPORATION | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249301-A1 | Regioselective Process for Preparing Benzimidazole Thiophenes | CYP3A4, CYP2C19, CYP2B6 | NEK2 1915/4885PLK1 1718/4885PLK3 2097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.